# A PK-PD Study of PSN821 in Type 2 Diabetes Patients (T2DM)

> **NCT01386099** · PHASE2 · COMPLETED · sponsor: **Prosidion Ltd.** · enrollment: 66 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** PSN821
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01386099
- **Lead sponsor:** Prosidion Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-01
- **Final completion:** 2012-05
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2012-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01386099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01386099, "A PK-PD Study of PSN821 in Type 2 Diabetes Patients (T2DM)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01386099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*